Company Description

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.

The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.

It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.

Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Inc.

Country	Canada
Founded	1998
IPO Date	Nov 8, 1999
Industry	Biotechnology
Sector	Healthcare
Employees	29
CEO	Jared Kelly

Contact Details

Address: 322 11th Avenue SW, Suite 804 Calgary, AB T2R 0C5 Canada
Phone	403 670 7377
Website	oncolyticsbiotech.com

Stock Details

Ticker Symbol	ONCY
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001129928
CUSIP Number	68237V103
ISIN Number	US68237V1035
Employer ID	98-0541667
SIC Code	2834

Key Executives

Name	Position
Jared Kelly J.D., L.L.M.	Chief Executive Officer and Director
Kirk J. Look C.A., CPA	Chief Financial Officer
Dr. Thomas C. Heineman M.D., Ph.D.	Chief Medical Officer
John McAdory	Executive Vice President of Strategy and Operations
Allison Hagerman P.Eng., P.M.P.	Chief Technology Officer
Jon Patton	Director of Investor Relations and Communication
Andrew P. Aromando	Chief Business Officer
Yujun Wu	Vice President and Head of Biostatistics
John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A.	Consultant

Latest SEC Filings

Date	Type	Title
Apr 8, 2026	F-10POS	Filing
Apr 8, 2026	F-10POS	Filing
Apr 8, 2026	F-10POS	Filing
Apr 8, 2026	F-10POS	Filing
Apr 8, 2026	F-10POS	Filing
Apr 8, 2026	F-10POS	Filing
Apr 8, 2026	F-10POS	Filing
Apr 8, 2026	F-10POS	Filing
Apr 8, 2026	F-10POS	Filing
Apr 8, 2026	F-10POS	Filing

View All SEC Filings